Triglav Investments D.O.O. raised its holdings in Cencora, Inc. (NYSE:COR – Free Report) by 140.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 33,000 shares of the company’s stock after buying an additional 19,300 shares during the quarter. Triglav Investments D.O.O.’s holdings in Cencora were worth $11,146,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Vestcor Inc lifted its holdings in Cencora by 0.5% in the third quarter. Vestcor Inc now owns 5,196 shares of the company’s stock valued at $1,624,000 after acquiring an additional 28 shares during the period. JFS Wealth Advisors LLC increased its position in shares of Cencora by 30.2% in the fourth quarter. JFS Wealth Advisors LLC now owns 125 shares of the company’s stock valued at $42,000 after buying an additional 29 shares in the last quarter. Apollon Wealth Management LLC increased its position in shares of Cencora by 0.5% in the fourth quarter. Apollon Wealth Management LLC now owns 6,527 shares of the company’s stock valued at $2,205,000 after buying an additional 30 shares in the last quarter. Accent Capital Management LLC increased its position in shares of Cencora by 36.1% in the fourth quarter. Accent Capital Management LLC now owns 113 shares of the company’s stock valued at $38,000 after buying an additional 30 shares in the last quarter. Finally, CYBER HORNET ETFs LLC boosted its position in shares of Cencora by 6.8% in the 4th quarter. CYBER HORNET ETFs LLC now owns 485 shares of the company’s stock worth $164,000 after buying an additional 31 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.
Cencora Trading Up 0.6%
Shares of COR stock opened at $269.21 on Friday. The firm has a 50-day moving average price of $298.56 and a 200 day moving average price of $333.91. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54. The company has a market capitalization of $52.38 billion, a price-to-earnings ratio of 20.65, a PEG ratio of 1.23 and a beta of 0.64. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40.
Cencora announced that its board has initiated a stock repurchase program on Thursday, May 21st that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to buy up to 3.9% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.
Cencora Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. Cencora’s payout ratio is presently 18.40%.
Analyst Ratings Changes
COR has been the topic of a number of research reports. Morgan Stanley set a $342.00 target price on shares of Cencora in a report on Friday, May 8th. Robert W. Baird reduced their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Leerink Partners reiterated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. JPMorgan Chase & Co. lifted their price objective on Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Finally, Weiss Ratings downgraded Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 22nd. Twelve research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus price target of $380.25.
Read Our Latest Research Report on Cencora
Cencora Company Profile
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Featured Articles
- Five stocks we like better than Cencora
- MarketBeat Week in Review – 05/25 – 05/29
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
